Cargando…
Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease
OBJECTIVE: Identification of brain regions susceptible to quantifiable atrophy in sporadic Creutzfeldt‐Jakob disease (sCJD) should allow for improved understanding of disease pathophysiology and development of structural biomarkers that might be useful in future treatment trials. Although brain atro...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164858/ https://www.ncbi.nlm.nih.gov/pubmed/33949799 http://dx.doi.org/10.1002/acn3.51290 |
_version_ | 1783701205167374336 |
---|---|
author | Younes, Kyan Rojas, Julio C. Wolf, Amy Sheng‐Yang, Goh M. Paoletti, Matteo Toller, Gianina Caverzasi, Eduardo Luisa Mandelli, Maria Illán‐Gala, Ignacio Kramer, Joel H. Cobigo, Yann Miller, Bruce L. Rosen, Howard J. Geschwind, Michael D. |
author_facet | Younes, Kyan Rojas, Julio C. Wolf, Amy Sheng‐Yang, Goh M. Paoletti, Matteo Toller, Gianina Caverzasi, Eduardo Luisa Mandelli, Maria Illán‐Gala, Ignacio Kramer, Joel H. Cobigo, Yann Miller, Bruce L. Rosen, Howard J. Geschwind, Michael D. |
author_sort | Younes, Kyan |
collection | PubMed |
description | OBJECTIVE: Identification of brain regions susceptible to quantifiable atrophy in sporadic Creutzfeldt‐Jakob disease (sCJD) should allow for improved understanding of disease pathophysiology and development of structural biomarkers that might be useful in future treatment trials. Although brain atrophy is not usually present by visual assessment of MRIs in sCJD, we assessed whether using voxel‐based morphometry (VBM) can detect group‐wise brain atrophy in sCJD. METHODS: 3T brain MRI data were analyzed with VBM in 22 sCJD participants and 26 age‐matched controls. Analyses included relationships of regional brain volumes with major clinical variables and dichotomization of the cohort according to expected disease duration based on prion molecular classification (i.e., short‐duration/Fast‐progressors (MM1, MV1, and VV2) vs. long‐duration/Slow‐progressors (MV2, VV1, and MM2)). Structural equation modeling (SEM) was used to assess network‐level interactions of atrophy between specific brain regions. RESULTS: sCJD showed selective atrophy in cortical and subcortical regions overlapping with all but one region of the default mode network (DMN) and the insulae, thalami, and right occipital lobe. SEM showed that the effective connectivity model fit in sCJD but not controls. The presence of visual hallucinations correlated with right fusiform, bilateral thalami, and medial orbitofrontal atrophy. Interestingly, brain atrophy was present in both Fast‐ and Slow‐progressors. Worse cognition was associated with bilateral mesial frontal, insular, temporal pole, thalamus, and cerebellum atrophy. INTERPRETATION: Brain atrophy in sCJD preferentially affects specific cortical and subcortical regions, with an effective connectivity model showing strength and directionality between regions. Brain atrophy is present in Fast‐ and Slow‐progressors, correlates with clinical findings, and is a potential biomarker in sCJD. |
format | Online Article Text |
id | pubmed-8164858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81648582021-06-15 Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease Younes, Kyan Rojas, Julio C. Wolf, Amy Sheng‐Yang, Goh M. Paoletti, Matteo Toller, Gianina Caverzasi, Eduardo Luisa Mandelli, Maria Illán‐Gala, Ignacio Kramer, Joel H. Cobigo, Yann Miller, Bruce L. Rosen, Howard J. Geschwind, Michael D. Ann Clin Transl Neurol Research Articles OBJECTIVE: Identification of brain regions susceptible to quantifiable atrophy in sporadic Creutzfeldt‐Jakob disease (sCJD) should allow for improved understanding of disease pathophysiology and development of structural biomarkers that might be useful in future treatment trials. Although brain atrophy is not usually present by visual assessment of MRIs in sCJD, we assessed whether using voxel‐based morphometry (VBM) can detect group‐wise brain atrophy in sCJD. METHODS: 3T brain MRI data were analyzed with VBM in 22 sCJD participants and 26 age‐matched controls. Analyses included relationships of regional brain volumes with major clinical variables and dichotomization of the cohort according to expected disease duration based on prion molecular classification (i.e., short‐duration/Fast‐progressors (MM1, MV1, and VV2) vs. long‐duration/Slow‐progressors (MV2, VV1, and MM2)). Structural equation modeling (SEM) was used to assess network‐level interactions of atrophy between specific brain regions. RESULTS: sCJD showed selective atrophy in cortical and subcortical regions overlapping with all but one region of the default mode network (DMN) and the insulae, thalami, and right occipital lobe. SEM showed that the effective connectivity model fit in sCJD but not controls. The presence of visual hallucinations correlated with right fusiform, bilateral thalami, and medial orbitofrontal atrophy. Interestingly, brain atrophy was present in both Fast‐ and Slow‐progressors. Worse cognition was associated with bilateral mesial frontal, insular, temporal pole, thalamus, and cerebellum atrophy. INTERPRETATION: Brain atrophy in sCJD preferentially affects specific cortical and subcortical regions, with an effective connectivity model showing strength and directionality between regions. Brain atrophy is present in Fast‐ and Slow‐progressors, correlates with clinical findings, and is a potential biomarker in sCJD. John Wiley and Sons Inc. 2021-05-05 /pmc/articles/PMC8164858/ /pubmed/33949799 http://dx.doi.org/10.1002/acn3.51290 Text en © 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Younes, Kyan Rojas, Julio C. Wolf, Amy Sheng‐Yang, Goh M. Paoletti, Matteo Toller, Gianina Caverzasi, Eduardo Luisa Mandelli, Maria Illán‐Gala, Ignacio Kramer, Joel H. Cobigo, Yann Miller, Bruce L. Rosen, Howard J. Geschwind, Michael D. Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease |
title | Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease |
title_full | Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease |
title_fullStr | Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease |
title_full_unstemmed | Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease |
title_short | Selective vulnerability to atrophy in sporadic Creutzfeldt‐Jakob disease |
title_sort | selective vulnerability to atrophy in sporadic creutzfeldt‐jakob disease |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164858/ https://www.ncbi.nlm.nih.gov/pubmed/33949799 http://dx.doi.org/10.1002/acn3.51290 |
work_keys_str_mv | AT youneskyan selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT rojasjulioc selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT wolfamy selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT shengyanggohm selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT paolettimatteo selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT tollergianina selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT caverzasieduardo selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT luisamandellimaria selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT illangalaignacio selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT kramerjoelh selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT cobigoyann selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT millerbrucel selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT rosenhowardj selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease AT geschwindmichaeld selectivevulnerabilitytoatrophyinsporadiccreutzfeldtjakobdisease |